Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone nasal spray for alcohol use disorder
2019-002859-42Phase 2Unknown
- Sponsor
- Opiant Pharmaceuticals
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naltrexone in alcohol use disorder (AUD) (3 arms), sponsored by Opiant Pharmaceuticals. Primary endpoint: Proportion of subjects with 2-level reduction in WHO Drinking Risk Level. Status: unknown.
02
Drugs
naltrexone
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2019-002859-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002859-42.